Canadian labeling, potency lawsuit includes CBD products

A CBD maker is among more than a dozen Canadian cannabis companies facing a labeling lawsuit.

The lawsuit, filed in Alberta by consumer Lisa Marie Langevin, accuses the companies and their subsidiaries of selling products “with THC or CBD content levels that were drastically different” from what was advertised.

Canada allows 15% variance for most THC and CBD products.  Langevin argues that some oils contained only 46% of the active THC labeled on the product. One CBD product had 52% of the labeled amount, she argues.

Defendants include Aurora Cannabis, Hexo Corp., Tilray Canada and Emblem Cannabis. The CBD maker is a subsidiary of Organigram.

The Cannabis Business Times first reported the lawsuit, which was filed June 16. Langevin is seeking class-action status in the Court of Queen’s Bench of Alberta.

The lawsuit in Canada comes as hemp-derived CBD companies in the U.S. also face a rise in class-action lawsuits over product claims.

On Wednesday, Hemp Industry Daily reported details of an FDA letter to Congress that showed many CBD products tested by the agency contained far less, and sometime more, of the cannabidiol advertised.